Literature DB >> 20121889

Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus.

C-Y Wong1, K-H Yiu, S-W Li, S Lee, S Tam, C-P Lau, H-F Tse.   

Abstract

AIMS: Increased dietary fish-oil consumption is associated with a reduced risk of coronary heart events and has pronounced effects on dyslipidaemia. However, the effects of fish-oil supplement on vascular function and metabolic profile in patients with Type 2 diabetes mellitus (DM) are unclear.
METHODS: In a double-blind placebo-controlled trial, we randomized 97 Type 2 DM patients without prior cardiovascular disease to fish-oil (4 g/day, n = 49) or olive-oil (with equivalent calories, as placebo, n = 48) supplements for 12 weeks. Assessment of vascular function with brachial artery flow-mediated dilation (FMD) and circulating levels of endothelial progenitor cells (EPCs), and metabolic parameters, high-sensitivity C-reactive protein (hsCRP), oxidative stress markers and renal function were examined before and after the supplement.
RESULTS: Despite a significant reduction in serum triglycerides (-0.47 mmol/l, P < 0.01), 12-week supplement of fish oil did not improve vascular function as determined by FMD (+0.16%, P = 0.83) and circulating EPC count (+4 cells/microl, P = 0.78). Furthermore, fish-oil supplement did not have any significant treatment effects on hsCRP, oxidative stress, low- and high-density lipoprotein and glycated haemoglobin (HbA(1c)) (all P > 0.05). In contrast, serum creatinine was lower (-4.5 micromol/l, P = 0.01) in fish-oil-treated patients as compared with control subjects.
CONCLUSIONS: This study demonstrated that 12 weeks of fish-oil supplement had no significant beneficial effect on vascular endothelial function, but improved renal function without changes in endothelial function, metabolic profiles, blood pressure, inflammation or oxidative stress in patients with Type 2 DM.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20121889     DOI: 10.1111/j.1464-5491.2009.02869.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  37 in total

Review 1.  Omega-3 polyunsaturated fatty acids improve endothelial function in humans at risk for atherosclerosis: A review.

Authors:  Kayla R Zehr; Mary K Walker
Journal:  Prostaglandins Other Lipid Mediat       Date:  2017-08-09       Impact factor: 3.072

Review 2.  Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment.

Authors:  Sandra J Hamilton; Gerald F Watts
Journal:  Rev Diabet Stud       Date:  2013-08-10

Review 3.  What are new avenues for renal protection, in addition to RAAS inhibition?

Authors:  Shinji Hagiwara; Phillip Kantharidis; Mark E Cooper
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

Review 4.  Effects of polyunsaturated fatty acid consumption in diabetic nephropathy.

Authors:  Haim Shapiro; Miryam Theilla; Joelle Attal-Singer; Pierre Singer
Journal:  Nat Rev Nephrol       Date:  2010-12-07       Impact factor: 28.314

5.  Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia.

Authors:  Ann C Skulas-Ray; Penny M Kris-Etherton; William S Harris; John P Vanden Heuvel; Paul R Wagner; Sheila G West
Journal:  Am J Clin Nutr       Date:  2010-12-15       Impact factor: 7.045

6.  Treatment for 6 months with fish oil-derived n-3 polyunsaturated fatty acids has neutral effects on glycemic control but improves dyslipidemia in type 2 diabetic patients with abdominal obesity: a randomized, double-blind, placebo-controlled trial.

Authors:  Feng Wang; Yanyan Wang; Yan Zhu; Xiaosong Liu; Hui Xia; Xian Yang; Guiju Sun
Journal:  Eur J Nutr       Date:  2016-12-02       Impact factor: 5.614

Review 7.  Omega-3 and omega-6 fatty acids and type 2 diabetes.

Authors:  Charlotte Jeppesen; Katja Schiller; Matthias B Schulze
Journal:  Curr Diab Rep       Date:  2013-04       Impact factor: 4.810

8.  Vitamin D and omega-3 trial to prevent and treat diabetic kidney disease: Rationale, design, and baseline characteristics.

Authors:  Ian H de Boer; Leila R Zelnick; Julie Lin; Debra Schaumberg; Lu Wang; John Ruzinski; Georgina Friedenberg; Julie Duszlak; Vadim Y Bubes; Andrew N Hoofnagle; Ravi Thadhani; Robert J Glynn; Julie E Buring; Howard D Sesso; JoAnn E Manson
Journal:  Contemp Clin Trials       Date:  2018-09-30       Impact factor: 2.226

9.  Effect of omega-3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial.

Authors:  Ellen K Hoogeveen; Johanna M Geleijnse; Daan Kromhout; Theo Stijnen; Eugenie F Gemen; Ron Kusters; Erik J Giltay
Journal:  Clin J Am Soc Nephrol       Date:  2014-08-07       Impact factor: 8.237

10.  Effects of long-term vitamin D and n-3 fatty acid supplementation on inflammatory and cardiac biomarkers in patients with type 2 diabetes: secondary analyses from a randomised controlled trial.

Authors:  Christine P Limonte; Leila R Zelnick; John Ruzinski; Andrew N Hoofnagle; Ravi Thadhani; Michal L Melamed; I-Min Lee; Julie E Buring; Howard D Sesso; JoAnn E Manson; Ian H de Boer
Journal:  Diabetologia       Date:  2020-10-24       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.